Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood (2019) 134 (Supplement_1): 3919.

https://doi.org/10.1182/blood-2019-130635

Published: 2019

Journal Articles

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Charles F. Lemaistre, MD, Ju-Hsien Chao, DO, Tonya Cox, BSN, RN, Jose Carlos Cruz, MD, William B. Donnellan, MD, Alireza Eghtedar, MD, Jared Holder, MA, Suman Kambhampati, MD, Shahbaz Malik, Michael B. Maris, MD, Marcello Rotta, MD, Frank Thomas Slovick, MD, Minoo Battiwalla, MD

Blood (2019) 134 (Supplement_1): 4780.

https://doi.org/10.1182/blood-2019-130640

Published: 2019

Journal Articles

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Zaid Al-Kadhimi, MD, Alireza Eghtedar, MD, Zartash Gul, MD, Wei Chen, PhD, Daryn Smith, Abhinav Deol, MD, Muneer H. Abidi, MD, Lawrence G Lum, MD, DSc, Divaya Bhutani, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 5471.

https://doi.org/10.1182/blood.V122.21.5471.5471

Published: 2013

Journal Articles

Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).

Alireza Eghtedar, MD, Hagop Kantarjian, MD, Elias Jabbour, MD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Elizabeth Burton, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD

Blood (2010) 116 (21): 3442.

https://doi.org/10.1182/blood.V116.21.3442.3442

Published: 2010

Journal Articles

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Alireza Eghtedar, MD, Srdan Verstovsek, MD, PhD, Jorge E. Cortes, MD, Zeev Estrov, MD, Jan A. Burger, MD, PhD, Carol Bivins, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Solly George, RN, Robert Newton, PhD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2010) 116 (21): 509.

https://doi.org/10.1182/blood.V116.21.509.509

Published: 2010

Journal Articles

Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

Alireza Eghtedar, MD, Stefan Faderl, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Tapan Kadia, MD, Sherry A. Pierce, RN, BS, Jenny Shan, PhD, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2010) 116 (21): 1085.

https://doi.org/10.1182/blood.V116.21.1085.1085

Published: 2010

NARROW

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

Email alerts

ASH Publications

American Society of Hematology

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).

Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML)

Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only